Skip to content
Terminus Peptides
Sign inContact
  • Research use only — not for human or veterinary use
  • 67 compound profiles, every source cited
  • 63 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status

Research profile · Peptide

Gonadorelin

Also known as GnRH, LHRH

Clinical — evidence level 4 of 4: Established clinical evidencePrescription only — UK regulatory status: Prescription-only medicine (UK)

Overview

The hypothalamic decapeptide controlling gonadotrophin release. A prescription-only medicine in the UK, licensed for diagnostic use.

Category
Peptide
Highest evidence level identified
Established clinical evidence
Last scientifically reviewed
22 August 2026
Last regulatory review
22 August 2026

Mechanism under investigation

Gonadorelin is synthetic gonadotrophin-releasing hormone, the ten-amino-acid hypothalamic peptide whose structure was solved in 1971 — work recognised with a Nobel Prize. Released in pulses roughly every one to two hours, it acts on GnRH receptors on pituitary gonadotropes to drive LH and FSH secretion. The pulsatility is the biology: the classic primate experiments showed that the same hormone delivered continuously shuts gonadotrophin secretion down by receptor desensitisation — the paradox on which both GnRH-agonist suppression therapy and pulsatile replacement rest. Its circulating half-life is a few minutes.

Research areas

  • Reproductive endocrinology
  • Endocrine diagnostics

These are fields in which the compound has been investigated. Listing a field is not a statement that anything was demonstrated within it.

Current evidence

In-vitro evidence

Cells, tissues or biochemical systems outside a living organism.

Exhaustively characterised: receptor structure, signalling, desensitisation kinetics and the medicinal chemistry of the agonist and antagonist analogues built on this scaffold.

Animal evidence

Studies in living non-human animals.

The foundational work is animal physiology — isolation of the porcine hormone, and the rhesus experiments separating pulsatile from continuous delivery.

Human observational evidence

Studies observing people without assigning an intervention.

Long clinical experience of the GnRH stimulation test in the assessment of hypothalamic–pituitary function, and of pulsatile GnRH in hypogonadotropic hypogonadism.

Clinical-trial evidence

Studies assigning an intervention to human participants.

The diagnostic use rests on decades of endocrine practice rather than modern trial programmes; pulsatile replacement for hypothalamic amenorrhoea and related conditions is supported by controlled physiology studies and specialist series. Large randomised programmes belong to the analogue drugs rather than to native gonadorelin.

Study limitations

  • The licensed UK indication is a single-dose pituitary function test; evidence for anything else belongs to different molecules or different delivery systems.
  • The hormone’s few-minute half-life means physiological effect depends entirely on pulsatile delivery — biology that bolus use does not reproduce.
  • Continuous or repeated non-pulsatile exposure suppresses the axis rather than stimulating it, an inversion popular accounts routinely miss.
  • Compounded gonadorelin products marketed alongside testosterone therapy abroad have no UK authorisation and no controlled outcome data.

UK regulatory context

Prescription-only medicine (UK)

A medicine that may lawfully be supplied in the UK only against a prescription from an appropriate practitioner.

Source: Gonadorelin 100 micrograms powder for solution for injection — Summary of Product Characteristics (opens medicines.org.uk in a new tab) (electronic Medicines Compendium)

Regulatory classification is jurisdiction-specific. A compound authorised elsewhere is not thereby authorised in the UK, and a supplier’s description of a substance does not determine how it is classified in law. See safety and regulation for the framework and the authoritative sources.

Safety and interpretation

Gonadorelin is a UK prescription-only medicine whose licence covers evaluating anterior pituitary gonadotrope function — a diagnostic given as a single injection in a supervised setting. Single diagnostic doses are well tolerated, with hypersensitivity reactions recognised rarely. Anything beyond diagnosis engages the desensitisation biology: sustained exposure suppresses the reproductive axis, which is the therapeutic point of the analogue drugs and an unmanaged consequence anywhere else. There is no UK-licensed therapeutic gonadorelin product, and axis manipulation outside specialist care has no safety framework.

References